Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
21.00
+0.49 (2.39%)
Jun 18, 2025, 4:00 PM - Market closed
Palvella Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Palvella Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $46.29, which forecasts a 120.43% increase in the stock price over the next year. The lowest target is $38 and the highest is $52.
Price Target: $46.29 (+120.43%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 16, 2025.
Analyst Ratings
The average analyst rating for Palvella Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 5 | 6 | 6 | 6 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 3 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $53 → $52 | Strong Buy | Maintains | $53 → $52 | +147.62% | May 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +80.95% | Apr 30, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +138.10% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +80.95% | Apr 1, 2025 |
| Stifel | Stifel | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +114.29% | Mar 26, 2025 |
Financial Forecast
Revenue This Year
n/a
from 5.93M
Revenue Next Year
n/a
EPS This Year
-4.43
from -7.83
EPS Next Year
-4.35
from -4.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | 14.8M |
| Avg | n/a | n/a | 5.9M |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.90 | -2.31 | -2.46 |
| Avg | -4.43 | -4.35 | -5.90 |
| Low | -15.42 | -12.42 | -13.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.